Allogene Therapeutics (ALLO) 10-Q2024 Q1 Quarterly report

Filed: 13 May 24, 4:03pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AACR, accomplished, advertising, affix, AID, algorithm, amicably, ancillary, Annex, ansegedleucel, Arbor, artificial, authorisation, authorised, autoreactive, behave, black, body, borne, box, cap, Catalent, CDMO, CE, cemacabtagene, Centre, Chemistry, chemoimmunotherapy, chronic, circumvention, CIRM, CLL, coincide, comparison, compensatory, core, Correctly, CRISPR, CTR, dedicated, deprioritized, device, diagnosed, dissolved, EFS, elapsed, eradicate, escrow, essential, exemplifying, flat, Food, Foresight, forum, GMP, GSPR, harmonized, Hong, honor, hyperinflammatory, IDE, IDSMB, inappropriately, ineffective, intelligence, iv, IVDR, Japan, judgment, Kong, laid, leaked, likewise, line, logistical, lymphocytic, minimal, minimum, MRD, newly, noncash, nonexclusive, Nordisk, Novo, occasionally, omitted, overpayment, Oxley, pathogenic, pausing, pendency, play, portal, premarket, prerequisite, presence, preserve, radiographically, reassessment, reconcile, referenced, referencing, refund, repaid, residual, retrain, robust, role, route, running, sanctioned, sending, shortfall, shortly, sought, sponsorship, stricter, therewith, trail, tribunal, TTM, undergo, undertaken, Vision

Removed: ALPHA, applying, Assuming, automating, barrier, carryover, ccRCC, CMO, Colorado, comprised, CPRA, curtailed, decided, deducting, DoR, electrical, Eric, evolve, facing, federally, formation, fourth, FTD, harmful, IGNITE, inclusive, initiating, insured, intercompany, lapsing, manual, mechanism, mg, migrated, noted, optimize, ORR, passed, phased, potency, procurement, progressing, progression, reclassified, repurchase, resigned, resurgence, rituximab, SAP, scheduled, Schmidt, secondary, secured, signaling, sponsoring, standardizing, strain, supervision, telecommunication, travel, typical, underwriting, UNIVERSAL, upgrade, utilizing, version, vigorously, Virginia, warehouse

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ALLO transcripts

ALLO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Allogene Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Chang, M.D., Ph.D., President and Chief Executive Officer of the Company, and I, Geoffrey Parker, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”); and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 13, 2024			/s/ David Chang
			David Chang, M.D., Ph.D.
			President and Chief Executive Officer
			(Principal Executive Officer)


Date: May 13, 2024			/s/ Geoffrey Parker
			Geoffrey Parker
			Chief Financial Officer
			(Principal Financial and Accounting Officer)

This certification shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of Section 18 of the Exchange Act. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.